

eTable 1. Results of Sensitivity Analyses With Exclusion of the Listed Trials

Removed trials	No. participants	Heterogeneity		Sensitivity analysis results	
		I <sup>2</sup> (%)	P	Ratio[95%CI]	P
X Jaïs <sup>1</sup>	2378	63.300	0.018	0.039[0.026,0.052]	<0.001
Diana Bonderman <sup>2</sup>	2202	73.100	0.002	0.042[0.025,0.058]	<0.001
Carlos Martinez <sup>3</sup>	2352	68.000	0.008	0.048[0.032,0.063]	<0.001
Irene M. Lang <sup>4</sup>	2204	75.400	0.001	0.046[0.028,0.064]	<0.001
Nicolas Coquoz <sup>5</sup>	2631	71.500	0.002	0.043[0.029,0.058]	<0.001
Joanna Pepke-Zaba <sup>6</sup>	1958	75.300	0.001	0.046[0.027,0.065]	<0.001
M. Bohacekova <sup>7</sup>	2554	75.400	0.001	0.046[0.030,0.062]	<0.001
R. Condliffe <sup>8</sup>	2166	66.400	0.011	0.039[0.025,0.054]	<0.001

eTable 2. Results of Sensitivity Analyses With Exclusion of the Listed Trials

Removed trials	No. participants	Control group	Heterogeneity		Sensitivity analysis results	
			I <sup>2</sup> (%)	P	OR[95%CI]	P
X Jaïs <sup>1</sup>	4423	PAH	0.000	0.633	2.600[1.150,5.880]	0.022
		Thromboembolism disease	0.000	0.480	5.590[2.120,14.740]	<0.001
Diana Bonderman <sup>2</sup>	4269	PAH	0.000	0.384	2.710[1.330,5.540]	0.006
		Thromboembolism disease	0.000	0.480	5.590[2.120,14.740]	<0.001
Carlos Martinez <sup>3</sup>	2317	PAH	0.000	0.633	2.940[1.620,5.330]	<0.001
		Thromboembolism disease	—	—	16.020[0.720,357.340]	0.080
Irene M. Lang <sup>4</sup>	4367	PAH	0.000	0.952	3.430[1.750,6.730]	<0.001
		Thromboembolism disease	0.000	0.480	5.590[2.120,14.740]	<0.001
Nicolas Coquoz <sup>5</sup>	4448	PAH	0.000	0.633	2.940[1.620,5.330]	<0.001
		Thromboembolism disease	—	—	5.000[1.800,13.850]	0.002

PAH: pulmonary arterial hypertension OR: odds ratio, 95%CI: 95%confidence intervals

## References

- Jaïs X, Ios V, Jardim C, et al. Splenectomy and chronic thromboembolic pulmonary hypertension. *Thorax* 2005;60:1031-4. doi:10.1136/thx.2004.038083, PMID: <http://www.ncbi.nlm.nih.gov/pubmed/16085731>
- Bonderman D, Wilkens H, Wakounig S, et al. Risk factors for chronic thromboembolic pulmonary hypertension. *The European respiratory journal* 2009;33:325-31. doi:10.1183/09031936.00087608, PMID: <http://www.ncbi.nlm.nih.gov/pubmed/18799507>

3. Martinez C, Wallenhorst C, Teal S, et al. Incidence and risk factors of chronic thromboembolic pulmonary hypertension following venous thromboembolism, a population-based cohort study in England. *Pulm Circ* 2018;8:2045894018791358. doi:10.1177/2045894018791358, PMID: <http://www.ncbi.nlm.nih.gov/pubmed/29985100>
4. Lang IM, Simonneau G, Pepke-Zaba JW, et al. Factors associated with diagnosis and operability of chronic thromboembolic pulmonary hypertension. A case-control study. *Thrombosis and haemostasis* 2013;110:83-91. doi:10.1160/th13-02-0097, PMID: <http://www.ncbi.nlm.nih.gov/pubmed/23677493>
5. Coquoz N, Weilenmann D, Stoltz D, et al. Multicentre observational screening survey for the detection of CTEPH following pulmonary embolism. *The European respiratory journal* 2018;51:1702505. doi:10.1183/13993003.02505-2017, PMID: <http://www.ncbi.nlm.nih.gov/pubmed/29563171>
6. Pepke-Zaba J, Delcroix M, Lang I, et al. Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry. *Circulation* 2011;124:1973-81. doi:10.1161/circulationaha.110.015008, PMID: <http://www.ncbi.nlm.nih.gov/pubmed/21969018>
7. Bohacekova M, Kaldararova M, Valkovicova T, et al. Risk factors detection in chronic thromboembolic pulmonary hypertension, a tool for risk quantification? *Bratislavské lekarske listy* 2016;117:577-582. doi:10.4149/bl\_2016\_112, PMID: <http://www.ncbi.nlm.nih.gov/pubmed/27826972>
8. Condliffe R, Kiely DG, Gibbs JS, et al. Prognostic and aetiological factors in chronic thromboembolic pulmonary hypertension. *The European respiratory journal* 2009;33:332-8. doi:10.1183/09031936.00092008, PMID: <http://www.ncbi.nlm.nih.gov/pubmed/18829679>